{"id":"brimonidine-ophthalmic-solution-0-1","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Ocular hyperemia (eye redness)"},{"rate":"10-15","effect":"Ocular allergic reactions"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5","effect":"Blurred vision"},{"rate":"5","effect":"Follicular conjunctivitis"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":{"setId":"e1ea003e-3dd9-41c7-9119-d1f209b9820b","title":"BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION, 0.15% SOLUTION/ DROPS [ALEMBIC PHARMACEUTICALS LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor (the fluid inside the eye) and enhances its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The drug has minimal systemic absorption when applied topically to the eye.","oneSentence":"Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:57.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07390578","phase":"PHASE4","title":"Upneeq vs. Lumify Ptosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-01","conditions":"Acquired Ptosis","enrollment":50},{"nctId":"NCT04007276","phase":"PHASE4","title":"The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-11-10","conditions":"Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":60},{"nctId":"NCT04741919","phase":"NA","title":"Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS)","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-11-25","conditions":"Primary Angle Glaucoma Closure Suspect","enrollment":200},{"nctId":"NCT00697541","phase":"PHASE2","title":"Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-05","conditions":"Erythematous Rosacea","enrollment":20},{"nctId":"NCT03192826","phase":"PHASE4","title":"Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2016-06-20","conditions":"Posterior Capsule Opacification, Ocular Hypertension","enrollment":79},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01525173","phase":"PHASE4","title":"A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":137},{"nctId":"NCT01250236","phase":"","title":"Effect of Brimonidine on Corneal Thickness","status":"UNKNOWN","sponsor":"Augenarztpraxis Breisach","startDate":"2010-12","conditions":"Impact of Brimonidine on the Cornea","enrollment":10},{"nctId":"NCT00652483","phase":"PHASE3","title":"Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":433},{"nctId":"NCT00440141","phase":"PHASE4","title":"Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Brimonidine ophthalmic solution 0.1%","genericName":"Brimonidine ophthalmic solution 0.1%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}